MBP146-78

MBP146-78 is an inhibitor of parasitic cGMP-dependent protein kinases (PKGs; IC₅₀s = 1.9 and 1 nM for the E. tenella and T. gondii enzymes, respectively).¹ It inhibits P. berghei sporozoite development into liver-stage parasites in HepG2 cells in a concentration-dependent manner.² MBP146-78 (50 mg/kg) prevents P. yoelii liver infection in P. yoelii-infected mice. It increases survival time in P. berghei-infected mice when administered at a dose of 50 mg/kg twice per day for eight days.¹ MBP146-78 (50 mg/kg two times per day) increases survival in T. gondii-infected mice and prevents secondary reinfection in the same mice.³

WARNING This product is not for human or veterinary use.

1. Diaz, C.A., Allocco, J., Powles, M.A., et al. Characterization of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG): Antiparasitic activity of a PKG inhibitor. Mol. Biochem. Parasitol. 146(1), 78-88 (2006).

2. Panchal, D., and Bhanot, P. Activity of a trisubstituted pyrrole in inhibiting sporozoite invasion and blocking malaria infection. Antimicrob. Agents Chemother. 54(10), 4269-4274 (2010).

3. Nare, B., Allocco, J.J., Liberator, P.A., et al. Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: Gamma interferon is required for efficacy. Antimicrob. Agents Chemother. 46(2), 300-307 (2002).